Please login to the form below

Not currently logged in
Email:
Password:

Teva begins second Phase III trial of oral MS treatment

Teva and Active Biotech have announced that patients are being enrolled for a global, double-blind phase III study of laquinimod for the treatment of multiple sclerosis
Teva and Active Biotech have announced that patients are being enrolled for a global, double-blind phase III study of laquinimod for the treatment of multiple sclerosis (MS).

The trial, known as BRAVO, aims to enrol 1,200 patients with relapsing-remitting multiple sclerosis (RRMS). It will evaluate the safety, tolerability and effectiveness of laquinimod and produce risk-benefit data for laquinimod versus Avonex, an injectable treatment.

The BRAVO trial will run alongside the ongoing ALLEGRO trial, a similar global, double-blind study involving around 1,000 patients.

"All currently approved multiple sclerosis (MS) treatments are administered via injection or infusion. The ability to provide a safe and effective oral treatment option would be a significant advancement for the treatment of MS," said Dr Timothy Vollmer medical director at the Rocky Mountain MS Center in Colorado, and principal investigator of the BRAVO study.

Results of a phase IIb study published in The Lancet, show that the orally-administrated drug significantly reduced magnetic resonance imaging (MRI) in RRMS patients by an average of 60 per cent.

Laquiniod, developed by Swedish company, Active Biotech, was licensed to Teva in 2004. Teva reports that laquiniod has demonstrated potential effectiveness in the treatment of other autoimmune diseases. The company expects to begin development of laquinimod for Crohn's disease and lupus nephritis in the near future.

16th July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics